A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.03.008
Abstract: Hypomethylating agent (HMA) failure myelodysplastic syndrome (MDS) patients have poor outcomes and urgent need for novel therapies. Hedgehog pathway signaling upregulation plays a central role in myeloid neoplasm pathogenesis and leukemia stem cell survival. We… read more here.
Keywords: hma failure; smoothened inhibitor; glasdegib; response ... See more keywords